• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    11/13/24 4:09:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email
    SC 13G/A 1 d847797dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Mineralys Therapeutics, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    603170101

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 603170101   Schedule 13G   Page 1 of 9

     

     1   

     Names of Reporting Persons

     

     Catalys Pacific Fund, LP

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 603170101   Schedule 13G   Page 2 of 9

     

     1   

     Names of Reporting Persons

     

     Catalys Pacific Fund GP, LP

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 603170101   Schedule 13G   Page 3 of 9

     

     1   

     Names of Reporting Persons

     

     Catalys Pacific, LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     OO


    CUSIP No. 603170101   Schedule 13G   Page 4 of 9

     

     1   

     Names of Reporting Persons

     

     Brian Taylor Slingsby

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     IN


    CUSIP No. 603170101   Schedule 13G   Page 5 of 9

     

    ITEM 1.     (a)    Name of Issuer:
         

    Mineralys Therapeutics, Inc. (the “Issuer”).

       (b)    Address of Issuer’s Principal Executive Offices:
         

    150 N. Radnor Chester Rd, Suite F200, Radnor, PA 19087

    ITEM 2.    (a)    Name of Person Filing:
         

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

         

    Catalys Pacific Fund, LP

         

    Catalys Pacific Fund GP, LP

         

    Catalys Pacific, LLC

         

    Brian Taylor Slingsby

       (b)    Address or Principal Business Office:
         

    The principal business address for Catalys Pacific Fund, LP, Catalys Pacific Fund GP, LP and Catalys Pacific, LLC is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

         

    The principal business address for Brian Taylor Slingsby is 1516 Bigelow Ave N, Seattle, WA 98109.

       (c)    Citizenship of each Reporting Person is:
         

    Brian Taylor Slingsby is a citizen of the United States. The other Reporting Persons are each entities organized under the laws of the Cayman Islands.

       (d)    Title of Class of Securities:
         

    Common Stock, par value $0.0001 per share (“Common Stock”).

       (e)    CUSIP Number:
         

    603170101

    ITEM 3.      

    Not applicable.


    CUSIP No. 603170101   Schedule 13G   Page 6 of 9

     

    ITEM 4.     Ownership.
       (a-c)
      

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of September 30, 2024, based upon 49,726,675 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole power
    to vote or
    to direct
    the vote:
         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Catalys Pacific Fund, LP

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Catalys Pacific Fund GP, LP

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Catalys Pacific, LLC

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Brian Taylor Slingsby

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Catalys Pacific Fund, LP is the beneficial owner of 8,681,245 shares of Common Stock, which includes 8,644,579 shares of Common Stock held of record by Catalys Pacific Fund, LP and 36,666 shares of Common Stock underlying stock options that are exercisable within 60 days of September 30, 2024.

    Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing director of Catalys Pacific, LLC. As a result, each of the Reporting Persons may be deemed to share beneficial ownership over the securities reported herein.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 603170101   Schedule 13G   Page 7 of 9

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 603170101   Schedule 13G   Page 8 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 13, 2024

     

    Catalys Pacific Fund, LP
    By:   Catalys Pacific Fund GP, LP, its General Partner
    By:   Catalys Pacific, LLC, its General Partner
    By:  

    /s/ Brian Taylor Slingsby

    Name:   Brian Taylor Slingsby
    Title:   Managing Director
    Catalys Pacific Fund GP, LP
    By:   Catalys Pacific, LLC, its General Partner
    By:  

    /s/ Brian Taylor Slingsby

    Name:   Brian Taylor Slingsby
    Title:   Managing Director
    Catalys Pacific, LLC
    By:  

    /s/ Brian Taylor Slingsby

    Name:   Brian Taylor Slingsby
    Title:   Managing Director

    /s/ Brian Taylor Slingsby


    CUSIP No. 603170101   Schedule 13G   Page 9 of 9

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $MLYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    3/7/2023$40.00Outperform
    Credit Suisse
    More analyst ratings

    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

      SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      11/13/24 4:27:48 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

      SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      11/13/24 4:19:46 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

      SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      11/13/24 4:09:56 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      4/25/25 7:01:59 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Samsara Biocapital Gp, Llc bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      3/17/25 9:05:47 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Akkaraju Srinivas bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      3/17/25 9:04:15 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

      RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

      1/4/24 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

      LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

      9/19/23 4:00:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

      7/10/24 7:50:59 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Mineralys Therapeutics with a new price target

      Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

      4/2/24 7:34:24 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Mineralys Therapeutics

      Evercore ISI initiated coverage of Mineralys Therapeutics with a rating of Outperform

      3/7/23 7:43:03 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Rodman David Malcom sold $173,774 worth of shares (11,366 units at $15.29), decreasing direct ownership by 10% to 106,669 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      5/15/25 7:01:41 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rodman David Malcom exercised 6,349 shares at a strike of $1.08, increasing direct ownership by 6% to 118,035 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      5/13/25 8:57:09 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      4/25/25 7:01:59 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for

      5/12/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

      RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care ConferenceDate: Wednesday, May 14, 2025Time: 4:35pm PDTFormat: PresentationWebcast Link    A live webcast of the presentation can be accessed under "News and Events" on the Investor Relations s

      5/7/25 8:00:00 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. Monday, May 12th @ 4:30 p.m. ET Domestic:1-800-717-1738International:1-646-307-1865Conference ID:53214Webcast:Link   A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of

      5/5/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    SEC Filings

    See more
    • SEC Form 144 filed by Mineralys Therapeutics Inc.

      144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      5/14/25 4:24:50 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Mineralys Therapeutics Inc.

      10-Q - Mineralys Therapeutics, Inc. (0001933414) (Filer)

      5/12/25 5:31:11 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

      5/12/25 4:13:55 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Financials

    Live finance-specific insights

    See more
    • Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for

      5/12/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. Monday, May 12th @ 4:30 p.m. ET Domestic:1-800-717-1738International:1-646-307-1865Conference ID:53214Webcast:Link   A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of

      5/5/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

      – Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor – – Data from Advance-HTN support the potential of lorundrostat as a best-in-class treatment for high-risk patients with uncontrolled or resistant hypertension who would normally be treated in a specialist setting – RADNOR, Pa., March 29, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmace

      3/29/25 2:30:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care